Plasma Elimination Half-Life of Oxybutynin
The plasma elimination half-life of oxybutynin is approximately 2 to 3 hours following oral administration. 1
Pharmacokinetic Profile
Following oral administration of oxybutynin chloride tablets, the drug demonstrates rapid absorption with maximum plasma concentrations (Cmax) achieved within approximately 1 hour, after which plasma concentrations decrease with an effective half-life of approximately 2 to 3 hours. 1 This relatively short half-life is consistent across both the R- and S-enantiomers of oxybutynin. 2
Key Pharmacokinetic Parameters:
Absorption: Oxybutynin is rapidly absorbed from the gastrointestinal tract, reaching peak plasma concentrations in less than 1 hour. 2
Bioavailability: The absolute systemic bioavailability is only about 6% (range 1.6 to 10.9%) for oral tablets due to extensive first-pass hepatic metabolism. 1, 2
Elimination: Plasma concentrations fall biexponentially with a terminal elimination half-life of approximately 2 hours. 2
Metabolism: Oxybutynin is extensively metabolized primarily by the cytochrome P450 enzyme system, particularly CYP3A4, with less than 0.1% of the administered dose excreted unchanged in the urine. 1
Clinical Implications of the Short Half-Life
The short 2-3 hour half-life has several important clinical consequences:
Dosing frequency: Multiple daily doses are necessary to maintain therapeutic plasma concentrations and sustained symptom control throughout the day. 1
Steady-state achievement: When administered on a regular dosing schedule, steady-state plasma concentrations are reached after approximately 8 days of treatment. 2
Interindividual variability: There is substantial interindividual variation in oxybutynin plasma concentrations following oral administration, which may contribute to variable clinical responses. 1, 2
Important Caveats
The short half-life of oxybutynin contrasts sharply with its active metabolite, desethyloxybutynin, which has pharmacological activity similar to the parent compound and may contribute to both therapeutic effects and adverse events. 1 The major pathway of elimination is hepatic metabolism rather than renal excretion, as almost no intact drug can be recovered in the urine. 2